Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Behaviour Phenotyping using Inertial Sensors (WEAR)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Portugal
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2019-01-01
End date: 2020-12-31
Duration (months): 24.0
Total project cost (EUR): 149820.0
EU funding (EUR): 149820.0
Participants: 1
Project status: CLOSED

Behavior is ultimately the observable output of the nervous system. Thus, to properly diagnose and monitor nervous system disorders it is crucial that we assess behavior comprehensively. However, every day clinical practice still relies mostly on subjective methods to evaluate behavior. The ability to adequately analyse behaviour is also critical during drug development, from the preclinical (animal models) to the clinical stages. Results from our ERC-funded work revealed that the combination of inertial sensor data with an unsupervised algorithm provides an optimal method for an easy to implement unbiased behavior classification that adequately captured the outcome of neural circuit’s computations. In this PoC we proposed to develop this technology into a product that provides a continuous, quantitative and comprehensive behavior assessment that is also versatile, covering the diverse spectrum from the pre-clinical to the clinical context. In this POC we will 1) refinement and validate of inertial sensors in animal models, 2) enable their integration into a Body Area Network, 3) Evolve our unsupervised algorithm into a stand-alone software that is versatile and easy to use. In addition to these technical aims, we propose to explore commercial opportunities and societal benefits, in particular in the medical and drug development sector. We will conduct market analysis and develop a business case for this product, while expanding industry contacts for production and commercialization. Our proposal will lead to a ground-breaking technical solution for quantitative, automated behavioral assessment in animal models of disease and humans that will have an important societal impact through innovation in diagnosis, disease monitoring, and drug development.

Keywords: inertial sensors,wearable,wireless,behaviour,unsupervised classification
A novel handheld probe coupled to mass spectrometer as a non-invasive tool for fast in vivo diagnosis of skin cancer (SKIN-CANCER-PROBE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Türkiye
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-08-01
End date: 2023-04-02
Duration (months): 24.0
Total project cost (EUR): 145355.52
EU funding (EUR): 145355.52
Participants: 1
Project status: CLOSED

Ambient mass spectrometry (AMS) has gained substantial attention in numerous research fields including clinical diagnosis as being a nondestructive, fast and simple approach. Despite of the advances in mass spectrometry (MS) one of its main disadvantages is the simultaneous introduction of the matrix and analyte to MS that results in low sensitivity associated with a high background and ion suppression, and frequent instrumental maintenance. Therefore, there is a need for a ground-breaking sampling tool that is combinable with MS and that does not compromise the above mentioned merits. Here we propose (i) to develop a novel handheld probe, which will have micro extraction mechanism for small molecules/biomarkers from the surface and can be combined with MS for real time targeted and untargeted analyses; (ii) to utilize the probe as a clinical diagnostic tool for noninvasive fast determination of skin cancer. The probe will be designed as a surface touch sampling device suitable for spot analysis and for continuous mode chemical imaging of surface. The device will be integrated with online desorption using a solvent junction and desorbed metabolites will be directed to MS. As proof-of-concept, skin cancer biomarkers and some other typical skin metabolites will be targeted during the probe development. Preliminary analyses with the probe will be conducted on the surface of agarose gel spiked with the selected metabolites mimicking artificial skin surface using MS in targeted mode. Upon development of the probe and prove of the detection of the biomarkers from the synthetic skin media the study will be extended to in vivo mice model with tumor. This novel probe will make a significant impact as rapid and reliable diagnostic tool. This project will open an opportunity for the researcher to develop her future career by implementing the novel probe in emerging research fields (e.g. clinical, forensic, etc.), where fast and reliable analytical tools are in high demand.

Keywords: in vivo sampling,solid phase microextraction,on line small molecule imaging,skin cancer,probe,mass spectrometric imaging,skin analysis,targeted analyis,untargeted analysis,biocompatible
Coexistence on the boundary of chaos (COEXIST)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2017-09-01
End date: 2019-08-31
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

This project is an exploration of the essence of chaos. Chaos and chaotic systems are by their very nature unpredictable. Paradoxically, the manner in which systems transition into chaotic regimes is highly structured and rigid. This contradiction can be explained mathematically through an elegant process called renormalization. Renormalization is like a microscope which can be used to observe the shape of fractals that appear on the boundary of chaos. One aspect of the structure of chaos is that such fractals on a large scale may look nothing like each other, but as the magnification factor on the microscope is increased they look more and more alike. This is expressed by saying that renormalization converges. Convergence of renormalization has been a consistent theme since the very inception of chaos theory, thus it was believed that the structure of chaos was thoroughly understood. In an unexpected twist, the applicant recently made the groundbreaking discovery that there are natural systems for which the renormalization sometimes is convergent and at other times degenerate. This reveals that the structure of chaos in fact is much more intricate than was previously imagined. Building on this radical discovery, the proposed project marks the start of an entirely new chapter in chaos theory. The objective is to explore this new notion of coexistence of convergent and degenerate behavior of renormalization, and to explain the consequences it has on the structure of chaos. The research will benefit the field of dynamical systems by expanding the knowledge of chaos into new and unexplored territory. It will also expand the reach of renormalization closer to systems which have relevance for the natural sciences as well as mathematics. The project hinges on the applicant joining the supervisor and members of the dynamical systems group at Imperial College, who are leading global experts, in order to learn cutting-edge techniques and spark new discussions.

Keywords: renormalization,one dimensional dynamics,universality
SpectraHow. Smart Raman sensor to speed up biopharma manufacture (SpectraHow)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Switzerland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-07-01
End date: 2019-09-30
Duration (months): 3.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Today, biopharmaceuticals generate global revenues of €145 billion, representing about 20% of the pharma market. The growth rate of biopharma, 8%, currently doubles that of conventional pharma. However, biopharma companies are facing an increased pressure for cheaper process development, faster time to market as well as more consistent production (reducing failure). Raman spectroscopy is a promising technology to improve bio processing and manufacture. Nevertheless, the corresponding data analysis of the complex spectra in biopharma is more challenging that conventional pharma, taking 2-5 months in order to acquire enough data and train a reliable predictive model. Founded in 2017, DataHow is a spin-off from the ETH Zürich, with the aim to accelerate biopharmaceutical process development and reduce risks in production through advanced algorithm-enabled digital solutions; SpectraHow is our scalable software based on advanced machine learning techniques, capable of accurately handling the large amounts of data generated, to automatically quantify the process dynamics and translate the information into direct decision support. Our algorithmic toolbox at TRL6 has been already tested in operational environment for different processes with several pharma companies, with a precision of up to 35% more accurate compared to commercial tools, and a smaller effort due to our automated calibration procedure. Next steps to take forward SpectraHow to commercialization are: improve usability with a Graphical User Interface, fine-tune our models and algorithms to further automate analysis, and show compatibility of our solution with third-party software tools to expand its functionality from R&D to production and to other spectroscopy techniques. In the booming Raman for pharma market valued at 2.5 billion in 2015, we forecast generate €21 Million in revenues in 2026 while creating 14 new jobs.

Keywords: biopharma,spectroscopy,drug development,drug manufacturing
Firm Growth and Market Power in the Global Economy (BIGlobal)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Individuals, Markets and Organisations
Panel description: Economics, finance and management
Countries involved: United Kingdom
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2017-12-01
End date: 2023-03-31
Duration (months): 64.0
Total project cost (EUR): 1313103.0
EU funding (EUR): 1313103.0
Participants: 1
Project status: SIGNED

According to the European Commission, to design effective policies for ensuring a “more dynamic, innovative and competitive” economy, it is essential to understand the decision-making process of firms as they differ a lot in terms of their capacities and policy responses (EC 2007). The objective of my future research is to provide such an analysis. BIGlobal will examine the sources of firm growth and market power to provide new insights into welfare and policy in a globalized world. Much of analysis of the global economy is set in the paradigm of markets that allocate resources efficiently and there is little role for policy. But big firms dominate economic activity, especially across borders. How do firms grow and what is the effect of their market power on the welfare impact of globalization? This project will determine how firm decisions matter for the aggregate gains from globalization, the division of these gains across different individuals and their implications for policy design. Over the next five years, I will incorporate richer firms behaviour in models of international trade to understand how trade and industrial policies impact the growth process, especially in less developed markets. The specific questions I will address include: how can trade and competition policy ensure consumers benefit from globalization when firms engaged in international trade have market power, how do domestic policies to encourage agribusiness firms affect the extent to which small farmers gain from trade, how do industrial policies affect firm growth through input linkages, and what is the impact of banking globalization on the growth of firms in the real sector. Each project will combine theoretical work with rich data from developing economies to expand the frontier of knowledge on trade and industrial policy, and to provide a basis for informed policymaking.
ICIQ Impulse for Talented Postdoctoral Fellows (I2-ICIQ Impulsion)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Co-funding of regional, national and international programmes (COFUND)-Fellowship programmes
Action type: Marie Skłodowska-Curie actions
Countries involved: Spain
Call: Co-funding of regional, national and international programmes (H2020-MSCA-COFUND-2017, 2017)
Start date: 2019-08-01
End date: 2024-09-30
Duration (months): 62.0
Total project cost (EUR): 1699200.0
EU funding (EUR): 849600.0
Participants: 1
Project status: SIGNED

I2: ICIQ Impulsion will impulse the professional career of 12 highly talented international fellows through the development of an innovative research programme based on interdisciplinarity, internationality and intersectoriality. This research programme will include a mandatory secondment (from two to six months) in a different research entity (academic and/or non-academic). I2: ICIQ Impulsion offers 19 research groups led by internationally renowned senior and tenure track researchers that develop excellent interdisciplinary chemical research in different areas of the chemical sciences. - Catalytic activation of chemical feedstock - Renewable energies from sunlight - CO2 capture and valorisation I2: ICIQ Impulsion fellows will have the freedom to - define an innovative research project within one of these areas of research - choose the Group Leader they would like to work with - choose a partner organisation to develop a secondment Being part of the I2: ICIQ Impulsion community will allow fellows to have: - Close supervision and mentoring by internationally renowned Group Leaders - Access to state-of-the-art scientific equipment and facilities - A personalised Career Development Plan - A tailored Training Programme - Secondments in international institutions - Networking opportunities - Dissemination and public engagement activities - Outstanding working conditions I2: ICIQ Impulsion is a very attractive programme for highly talented postdoctoral researchers looking for further opportunities in research. It has been designed to enable the maximum impact on immediate and long-term career prospects for the fellows, both in academia and in the private sector. I2: ICIQ Impulsion will also contribute to improve the attractiveness of Catalonia, Spain and Europe as a leading destination for research and innovation, boost the international visibility of ICIQ and further increase the quality of research and innovation developed in the European Research Area (ERA)

Keywords: postdoctoral training,chemistry
MicroRNA determinants of the balance between effector and regulatory T cells in vivo (DevoTed_miR)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Immunity, Infection and Immunotherapy
Panel description: The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
Countries involved: Portugal
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-07-01
End date: 2021-02-28
Duration (months): 68.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: CLOSED

T lymphocytes display potent pro- or anti-inflammatory properties, which typically associate with distinct effector (Teff) versus regulatory (Treg) cell subsets. Based on published and our preliminary data showing a major impact of microRNAs on T cell differentiation and (auto)immune pathology, my proposal aims to dissect the miRNA networks that control the balance between Teff and Treg subsets in vivo, in various experimental models of infection and autoimmunity. We will focus on three critical mediators of T cell functions: interferon-gamma (IFN-g) and interleukin-17A (IL-17), highly pro-inflammatory Teff cytokines; and Foxp3, the transcription factor that confers Treg suppressive properties. To track the activity of these key genes, we will generate a new Ifng/ Il17/ Foxp3 triple reporter mouse, from which we will isolate Teff and Treg subsets to determine their genome-wide miRNA profiles and specific signatures in vivo. We will investigate both natural (thymic-derived and present in naïve mice) and induced (in the periphery upon challenge) Teff and Treg subsets, as they make distinct contributions to the immune response. We will identify miRNAs selectively expressed in Teff (Ifng+ or Il17+) versus Treg (Foxp3+) subsets of various lineages (CD4+, CD8+, gamma-delta or NKT) in each in vivo model; assess whether they are induced during thymic development or upon peripheral activation; and determine the robustness of subset-specific miRNA profiles across various in vivo challenges. We will then use loss- and gain-of-function strategies to define the individual miRNAs that impact Teff or Treg differentiation and disease pathogenesis; dissect the external cues and intracellular mechanisms that regulate miRNA expression; and identify the mRNA networks controlled by key miRNAs in Teff and Treg differentiation. I expect this project to provide major conceptual and experimental advances towards manipulating miRNAs either to boost immunity or to treat autoimmunity.

Keywords: t cell differentiation,microrna,cytokines
PREcession-based drive mechanisms for high-PREcision energy-efficient POSitionining devices (PRE2POS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Action type: SME instrument
Countries involved: Spain,Italy,Italy
Call: Engaging SMEs in space research and development (H2020-SMEINST-2-2016-2017, 2016)
Start date: 2016-10-01
End date: 2019-11-30
Duration (months): 38.0
Total project cost (EUR): 2988226.25
EU funding (EUR): 2091758.38
Participants: 3
Project status: CLOSED

PhiDrive and Arquimea´s Pre2Pos project is a Phase 1 winning project from the Horizon 2020 SME Instrument Space call of September 2014. The project is based on the industrialisation and commercialisation of rotary actuators, using an innovative motor which takes advantage of the micrometric deformation displacement of piezoelectric stacks, shape memory alloys and other smart materials to achieve infinite rotary or linear motion. Our plan is to include these rotary actuators in key equipment and mechanisms used in Space and in particular on satellites, such as Solar Array Drive Mechanisms (SADMs), Antenna Pointing Mechanisms (APMs) or Deployment Mechanisms (DMs), where high precision, low weight, energy efficiency and low manufacturing costs are constantly sought by End Users. Since receiving the notification of our Phase 1 success, we, PhiDrive, have been working intensively on the Feasibility Study for our project. We have analysed and planned our strategy for the future technical and business development, in order to maximize the exploitation of our innovative technology and its application within the Space industry. In this respect, we have succeded in recruiting an excellent and experience partner, Arquimea. Also, our first motor prototypes have already demonstrated the effectiveness of the technology, with the mechanical characteristics complying with the expected and desired results. Finally, our consolidated Pre2Pos business plan indicates that we will be able to sell 450 products from 2018 to 2022, bringing accumulated revenues of over €22.5 million, while at the same time creating more than 20 new positions in both companies.

Keywords: motor,drive,rotary actuator,position,piezoelectric stack,satellite,sadm,hdrm
Joint Initiative for hydrogen Vehicles across Europe 2 (JIVE 2)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Fuel Cells and Hydrogen
Action type: Innovation actions
Partnership: FCH2 (Art-187)
Countries involved: Germany,Germany,Germany,Germany,Spain,Iceland,Germany,Germany,Norway,Belgium,Slovenia,Sweden,Sweden,Latvia,France,France,France,France,France,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,United Kingdom,Portugal,Denmark,United Kingdom,United Kingdom
Call: Large scale demonstration in preparation for a wider roll-out of fuel cell bus fleets (FCB) including new cities – Phase two (H2020-JTI-FCH-2017-1, 2017)
Start date: 2018-01-01
End date: 2025-06-30
Duration (months): 90.0
Total project cost (EUR): 89972571.29
EU funding (EUR): 25000000.0
Participants: 35
Project status: SIGNED

The spotlight on health impacts of poor air quality and the renewed focus on reducing GHG emissions in recent years provide a strong impetus for cities to seek clean, low carbon transport solutions. When it comes to meeting growing demands for public transport and addressing environmental issues, hydrogen fuel cell (FC) buses offer significant potential. A commercialisation process for FC buses is underway, through which a shared vision has been agreed between vehicle suppliers and their customers. This is based on reducing costs through scale via a phased approach of pre-commercial demonstrations that will provide the evidence for wider uptake of these vehicles in the 2020s. The first step in upscaling FC bus deployment is underway through the JIVE project, which began in January 2017. JIVE 2 is its successor and is Europe’s most ambitious FC bus project to date: 156 buses in 10 cities across five countries. JIVE 2 involves regions with experience of the technology scaling up fuel cell bus fleets (e.g. Cologne), and those seeking to build their knowledge and experience by demonstrating FC buses in small fleets for the first time (e.g. Auxerre). All deployment locations in JIVE 2 share an ambition to increase the size of their FC bus fleets following successful initial demonstrations, hence the participating cities/regions will be natural locations for larger scale roll-out of the technology in the 2020s. A comprehensive data monitoring and assessment exercise will capture the relevant evidence to inform next steps for the sector, and the project’s impacts will be maximised by a high-impact dissemination campaign. This will involve reaching wide audiences via various channels, including a series of international Zero Emission Bus Conferences. The JIVE and JIVE 2 projects together will see the deployment and operation of nearly 300 FC buses in 16European cities/regions, thus providing a sound basis for further development of this sector.

Keywords: hydrogen fuel cell buses,zero emission